873 reports of this reaction
1.7% of all VORICONAZOLE reports
#10 most reported adverse reaction
ASPERGILLUS INFECTION is the #10 most commonly reported adverse reaction for VORICONAZOLE, manufactured by Roerig. There are 873 FDA adverse event reports linking VORICONAZOLE to ASPERGILLUS INFECTION. This represents approximately 1.7% of all 52,026 adverse event reports for this drug.
VORICONAZOLE has an overall safety score of 88 out of 100. Patients taking VORICONAZOLE who experience aspergillus infection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASPERGILLUS INFECTION is a less commonly reported adverse event for VORICONAZOLE, but still significant enough to appear in the safety profile.
In addition to aspergillus infection, the following adverse reactions have been reported for VORICONAZOLE:
ASPERGILLUS INFECTION has been reported as an adverse event in 873 FDA reports for VORICONAZOLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASPERGILLUS INFECTION accounts for approximately 1.7% of all adverse event reports for VORICONAZOLE, making it a notable side effect.
If you experience aspergillus infection while taking VORICONAZOLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.